Keros Therapeutics, Inc.
Keros Therapeutics develops protein therapeutics for disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins. Its candidates target conditions affecting tissues including skeletal muscle, bone and blood. Keros’ lead candidate, rinvatercept, is in development for Duchenne muscular dystrophy and amyotrophic lateral sclerosis. Its most advanced candidate, elritercept, is being developed for cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes and myelofibrosis. Keros earns money through an exclusive license agreement with Takeda for the development, manufacture and commercialization of elritercept worldwide outside of mainland China, Hong Kong and Macau. The agreement became effective on January 16, 2025. Keros is headquartered in Lexington, Massachusetts.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $KROS in the last 30 days.
See all $KROS insider activity →Keros Therapeutics reported Q3 GAAP EPS of $0.70, beating estimates by $1.72, and revenue of $40M, exceeding expectations by $26.11M. The company also announced a $5M share buyback following a $20M milestone.
Keros Therapeutics, Inc. (KROS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2026 Financial Results • First patient dosed in Phase 2 clinical trial of rinvatercept in patients with Duchenne muscular dystrophy in September 2026 • Nominated KER-206, a novel ligand trap desi
Keros Therapeutics (NASDAQ:KROS) initiated a Phase II study of rinvatercept for Duchenne muscular dystrophy (DMD), expecting data in early 2027. The treatment aims to increase muscle regeneration. Keros also plans an ALS trial in 2027, targeting muscle preservation. The company will use DEXA scans and functional assessments to evaluate progress.
Over the past 7 days, AlphAI's AI scored 3 news stories mentioning KROS (Keros Therapeutics, Inc.). Coverage has skewed bullish: 3 bullish, 0 neutral, and 0 bearish.
Recent KROS coverage spans financial news, earnings and technology.
Earnings beat suggests stronger-than-expected performance.
Earnings beat loss expectations and a key clinical milestone may boost sentiment.
The trial start introduces a new clinical milestone that could drive future upside if data are positive.
Milestone payment reinforces cash runway and may support short‑term buying.
The cash inflow improves Keros' balance sheet and validates its partnership, likely supporting the stock.
AlphAI scores every news story that mentions KROS with an AI model for sentiment and relevance, and aggregates insider trades from Keros Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Keros Therapeutics reported Q3 GAAP EPS of $0.70, beating estimates by $1.72, and revenue of $40M, exceeding expectations by $26.11M. The company also announced a $5M share buyback following a $20M milestone.
Keros Therapeutics, Inc. (KROS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2026 Financial Results • First patient dosed in Phase 2 clinical trial of rinvatercept in patients with Duchenne muscular dystrophy in September 2026 • Nominated KER-206, a novel ligand trap desi
Keros Therapeutics (NASDAQ:KROS) initiated a Phase II study of rinvatercept for Duchenne muscular dystrophy (DMD), expecting data in early 2027. The treatment aims to increase muscle regeneration. Keros also plans an ALS trial in 2027, targeting muscle preservation. The company will use DEXA scans and functional assessments to evaluate progress.
Disc Medicine's Phase 3 trial for a rare light-sensitivity disorder met all endpoints, shares rose 38.86%. Silence Therapeutics agreed to a $1.3B acquisition by Merck KGaA at a 130% premium, shares up 125.58%. Other rare blood disorder-focused companies also saw gains. Disc plans FDA resubmission by 2026 end, Silence deal expected Q1 2027.
Keros Therapeutics, Inc. (KROS) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Keros Therapeutics to Receive Additional Development Milestone Payment from Partner Takeda LEXINGTON, Mass., September 29, 2026, (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing an
Keros Therapeutics, Inc. (KROS) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Keros Therapeutics Announces the First Patient Dosing in the Phase 2 Clinical Trial Evaluating Rinvatercept in DMD • Initial data expected in the first half of 2027 LEXINGTON, Mass., September 28, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: K
Keros Therapeutics (KROS) authorized a $5M share buyback following a $20M milestone payment from Takeda for its elritercept drug. The Phase 3 trial for anaemia began, and the company may repurchase shares based on market conditions. KROS stock rose 3.4% in after-hours trading.
Keros Therapeutics (KROS) received a $20M milestone payment from Takeda for the first patient dosed in the Phase III ELRiSE study. The company has no marketed products and limited revenue, but the payment adds financial flexibility. KROS will distribute 25% of the proceeds to stockholders and use the rest to advance its rinvatercept program. Cash reserves were $257.6M at June 30, 2026, with shares down 46.8% year-to-date.
Keros Therapeutics (KROS) reported a Q2 2026 loss of $1.45 per share, wider than estimates, with revenues falling to zero. The company's focus is on rinvatercept, with clinical trials ongoing. KROS has $257.6M in cash, expected to last until mid-2028. Shares have dropped 46.8% YTD, trading at 37.1X forward sales.
Keros Therapeutics (NASDAQ:KROS) said it received a $20 million development milestone from Takeda (NYSE:TAK) after the first patient was dosed in Phase 3 ELRiSE MDS. The trial compares elritercept with epoetin alfa for anemia in low-to-intermediate-risk MDS. Keros previously got a $200 million upfront payment and may earn over $1.1 billion more milestones plus royalties, and plans to distribute 25% of the $20 million net proceeds to shareholders.
